Moreover, as recently described, GLP-1 RAs are able to induce non-alcoholic steatohepatitis resolution, reduction in weight and fat content, improvements in hepatic injury biomarkers, and non-alcoholic fatty liver disease in a high percentage of T2D patients (33). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.